 Proto-Oncogene Proteins p21(ras)
"Proto-Oncogene Proteins p21(ras)" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular proteins encoded by the H-ras, K-ras and N-ras genes. The proteins have GTPase activity and are involved in signal transduction as monomeric GTP-binding proteins. Elevated levels of p21 c-ras have been associated with neoplasia. This enzyme was formerly listed as EC 3.6.1.47.
| Descriptor ID |
D016283
|
| MeSH Number(s) |
D08.811.277.040.330.300.400.500.600 D12.644.360.525.500.600 D12.776.157.325.515.500.600 D12.776.476.525.500.600 D12.776.624.664.700.200
|
| Concept/Terms |
Proto-Oncogene Proteins p21(ras)- Proto-Oncogene Proteins p21(ras)
- p21 c-ras
- c-ras, p21
- p21 c ras
- p21(c-ras)
- p21(ras)
- Proto-Oncogene Protein ras
- Proto Oncogene Protein ras
- ras, Proto-Oncogene Protein
- Proto-Oncogene Proteins c-ras
- Proteins c-ras, Proto-Oncogene
- Proto Oncogene Proteins c ras
- c-ras, Proto-Oncogene Proteins
- ras Proto-Oncogene Product p21
- ras Proto Oncogene Product p21
- ras Proto-Oncogene Protein p21
- ras Proto Oncogene Protein p21
- c-ras Proteins
- c ras Proteins
- Proto-Oncogene Protein p21(ras)
Proto-Oncogene Protein p21(c-Ha-ras)- Proto-Oncogene Protein p21(c-Ha-ras)
- p21(c-Ha-ras)
- p21 c-Ha-ras
- c-Ha-ras, p21
- p21 c Ha ras
- c-Ha-ras p21
- c Ha ras p21
- p21, c-Ha-ras
- p21 c-H-ras
- c-H-ras, p21
- p21 c H ras
Proto-Oncogene Protein p21(c-Ki-ras)- Proto-Oncogene Protein p21(c-Ki-ras)
- p21(c-Ki-ras)
- p21 c-Ki-ras
- c-Ki-ras, p21
- p21 c Ki ras
- c-Ki-ras p21
- c Ki ras p21
- p21, c-Ki-ras
- p21 c-K-ras
- c-K-ras, p21
- p21 c K ras
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins p21(ras)".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins p21(ras)".
This graph shows the total number of publications written about "Proto-Oncogene Proteins p21(ras)" by people in this website by year, and whether "Proto-Oncogene Proteins p21(ras)" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2009 | 1 | 1 | 2 | | 2011 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Lin DM, Javidiparsijani S, Vardouniotis A, Buckingham L, Reddy SB, Gattuso P. Ectopic Thyroid Tissue: Immunohistochemistry and Molecular Analysis. Appl Immunohistochem Mol Morphol. 2018 Nov/Dec; 26(10):734-739.
-
Bishehsari F, Zhang L, Barlass U, Preite NZ, Turturro S, Najor MS, Shetuni BB, Zayas JP, Mahdavinia M, Abukhdeir AM, Keshavarzian A. KRAS mutation and epithelial-macrophage interplay in pancreatic neoplastic transformation. Int J Cancer. 2018 10 15; 143(8):1994-2007.
-
Dauer P, Zhao X, Gupta VK, Sharma N, Kesh K, Gnamlin P, Dudeja V, Vickers SM, Banerjee S, Saluja A. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Cancer Res. 2018 03 01; 78(5):1321-1333.
-
Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, Buczkowski KA, Grant AK, Ullas S, Rhee K, Cavanaugh JD, Neupane NP, Christensen CL, Herter JM, Makrigiorgos GM, Hodi FS, Freeman GJ, Dranoff G, Hammerman PS, Kimmelman AC, Wong KK. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016 06 16; 1(9):e87415.
-
Turturro SB, Najor MS, Ruby CE, Cobleigh MA, Abukhdeir AM. Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. Breast Cancer Res Treat. 2016 Feb; 156(1):33-43.
-
Xicola RM, Gagnon M, Clark JR, Carroll T, Gao W, Fernandez C, Mijic D, Rawson JB, Janoski A, Pusatcioglu CK, Rajaram P, Gluskin AB, Regan M, Chaudhry V, Abcarian H, Blumetti J, Cintron J, Melson J, Xie H, Guzman G, Emmadi R, Alagiozian-Angelova V, Kupfer SS, Braunschweig C, Ellis NA, Llor X. Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. Clin Cancer Res. 2014 Sep 15; 20(18):4962-70.
-
Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013 Jun 01; 73(11):3248-61.
-
Janardhan SV, Praveen K, Marks R, Gajewski TF. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells. PLoS One. 2011; 6(9):e24931.
-
Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009 Oct 28; 29(43):13543-56.
-
Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009 Jan; 4(1):12-21.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|